Open AccessPlasma alpha‐synuclein detected by single molecule array is increased in PD
Author(s) -
Ng Adeline S. L.,
Tan Yi Jayne,
Lu Zhonghao,
Ng Ebonne Y. L.,
Ng Samuel Y. E.,
Chia Nicole S. Y.,
Setiawan Fiona,
Xu Zheyu,
Tay Kay Yaw,
Prakash Kumar M.,
Au Wing Lok,
Tan EngKing,
Tan Louis C. S.
Publication year - 2019
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.729
Subject(s) - medicine , alpha (finance) , alpha synuclein , bonferroni correction , plasma levels , parkinson's disease , endocrinology , disease , clinical psychology , psychometrics , construct validity , statistics , mathematics
We utilized ultrasensitive single molecule technology to measure plasma alpha‐synuclein in 221 subjects (51 controls, 170 PD ). Plasma alpha‐synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD , alpha‐synuclein levels did not vary by H&Y stage or UPDRS motor scores but were significantly higher in PD patients with poorer cognition ( MMSE ≤ 25) than controls ( P = 0.016, Bonferroni corrected P = 0.047). Alpha‐synuclein levels quantified using ultrasensitive single molecule technology discriminate PD from controls and correlate with cognitive severity. These preliminary findings require independent validation to determine the utility of this assay.